Craig W. Philips Appointed Interim CEO of Kv1.3 Therapeutics, Inc.

Home > Press Release > Craig W. Philips Appointed Interim CEO of Kv1.3 Therapeutics, Inc.

Craig W. Philips Appointed Interim CEO of Kv1.3 Therapeutics, Inc.

October 21, 2017. Seattle, WA — The Board of Directors of Kv1.3 Therapeutics, Inc. today announced the appointment of Craig W. Philips as the interim Chief Executive Officer for the company. “I am very excited to be named to this position. The company is focused on developing a novel drug for a rare disease. The rare disease market segment is an appealing sector in which to focus due to the significant medical need for innovative products, the faster path-to-market, and the financial incentives available to companies in this sector. I look forward to advancing our efforts with dalazatide, our lead drug and
look forward to exploring strategic alternatives for the company.”

Mr. Philips has over 30 years of industry experience across both large pharmaceutical companies as well as emerging companies. He spent over 20 years with major pharmaceutical companies including Bristol Myers, Schering Plough (now Merck) and Bayer, before focusing on emerging and start-up biotechnology focused companies. He was involved in founding and launching several biotech companies and is on the Board of Directors for several private life science companies. Mr. Philips received his bachelor’s degree and his MBA from The Ohio State University. He is an active volunteer at the University of Washington and Seattle University where he supports various life science innovation activities.

About Dalazatide
Dalazatide is a novel Kv1.3 blocker, a first-in-class drug being developed initially for rare autoimmune diseases including as a potential treatment of myositis – a rare autoimmune disease with significant unmet medical need. Dalazatide is the lead drug in Kv1.3 Therapeutics’ patent-protected family of Kv1.3 blockers and has demonstrated activity in a variety of autoimmune disease models and a proof-of-concept prototypical Phase 1b clinical trial. In addition to showing clinical activity in a patient population, studies have also reinforced the immune sparing features of this drug. Kv1.3 Therapeutics, Inc.’s products provide potential breakthrough solutions in the toolkit for physicians managing patients with rare and debilitating autoimmune diseases.

About Kv1.3 Therapeutics Inc.
Kv1.3 Therapeutics is a Seattle-based, clinical stage biopharmaceutical company. The company is committed to transforming treatment alternatives for patients with rare and autoimmune diseases. Kv1.3 Therapeutics is focused on developing a unique group of Kv1.3 blockers for potential management of rare diseases such as myositis, a rare and debilitating disease which affects over 16,000 Americans. Kv1.3 Therapeutics’ lead compound, dalazatide – has completed three Phase 1 trials. The company actively collaborates with private, academic, and industry partners to advance our research and clinical activities in rare diseases. For more information please visit us at Kv13Therapeutics.com.

Contact
For additional information please contact us at info@kv13therapeutics.com or at 206-812-1405.

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kv1.3 Therapeutics, Inc.’s plans for pre-clinical and clinical studies, regulatory filings, anticipated drug effects in human subjects, business performance and investment performance. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kv1.3’s business which could significantly affect expected results. All forwardlooking statements are qualified in their entirety by this cautionary statement, and Kv1.3 undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.